医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience

2014年11月06日 PM09:00
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.

Complying with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines, the company offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. Vanta Bioscience also offers toxicology services using alternative methods for the Cosmetics industry.

The state-of-the-art facility is GLP and AAALAC accredited, is armed with high-end equipment, and has infrastructure like ‘Individually ventilated Cages’ and ‘Intelligent Building Management’ systems. The facility houses GLP trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND filings.

Speaking on the occasion, Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.”

Gerard Schwickerath, Vice President and General Manager, Vanta Bioscience, said: “Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organization will continue under the direction of GVK BIO. We are delighted to transition into an organization that can expand our offerings and provide further opportunities to our clients and staff.”

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of integrated services across the R&D and manufacturing value chain with a focus on speed and quality. GVK BIO capabilities include Discovery Services, Contract Manufacturing, Formulations, Informatics and Clinical Development. www.gvkbio.com

About Vanta Bioscience

Vanta Bioscience offers safety and efficacy assessment services for clients in the pharmaceutical, biotech, medical device, cosmetics, agriculture, food supplements, feed additives and chemical industries, complying with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines. www.vantabio.com

CONTACT

GVK Biosciences
Dorothy Paul
Phone: (91) 40 6692 9904
(D)
dorothy.paul@gvkbio.com
or
Vanta
Bioscience
Gerard Schwickerath
Phone: (1) 515-822-1875
Gerard.Schwickerath@vantabio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Q4 and FY18 Financial Results
  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益
  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model